ArticleTheranostics2026
Epigenetic subtypes of high-grade T1 bladder cancer reveal intra-tumor heterogeneity and distinct interactions with tumor microenvironment.
Article in Theranostics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rationale: High-grade T1 (HGT1) Non-Muscle Invasive Bladder Cancer (NMIBC) is a clinically heterogeneous disease characterized by unpredictable treatment responses and limited tools for recurrence prediction. Despite advances in molecular classification, patient stratification still relies mainly on clinicopathological features, providing limited precision. Methods: In this study, we integrated bulk chromatin profiling with single-nuclei RNA-seq, immunohistochemistry, and spatial transcriptomics to define epigenetic subtypes of HGT1, characterize their heterogeneity, and explore tumor-microenvironment interactions. Results: We identified distinct chromatin landscapes distinguishing urothelial (URO) and micropapillary (MP) histological variants of high-risk HGT1. Three main epigenetic states emerged: luminal-like inflammatory (LLI) and basal-like (BL) subtypes within URO tumors, and a separate signature unique to MP tumors. Single-cell and spatial analyses confirmed intratumoral heterogeneity and revealed subtype-specific microenvironmental contexts.Approximately 40% of URO tumors exhibited spatially distinct coexisting LLI and BL components. BL regions, enriched for angiogenesis and hypoxia pathways, were preferentially located near vascular stroma, whereas LLI regions were situated at the tumor core. MP tumors displayed a markedly different microenvironment with abundant cancer-associated fibroblasts (CAFs) and M2-polarized macrophages intermingled with tumor cells, suggesting an immunosuppressive niche that may underlie their poor prognosis. In contrast, URO tumors showed a more immune-excluded phenotype. Conclusion: These findings provide a detailed molecular and spatial map of HGT1 heterogeneity, linking epigenetic states to tumor architecture and microenvironmental interactions. They underscore the need for subtype-specific therapeutic strategies to effectively address the biological diversity already present in HGT1 bladder cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.